Aspirin resistance;Aspirin Direnci

Anadolu Kardiyoloji Dergisi

Volumn 4, Issue 1, 2004, Pages 59-62

  Yilmaz, Mehmet Birhan ^a,b   Balbay, Yücel ^a   Korkmaz, Şule ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Aspirin resistance; Cyclooxygenase; Thrombocytes

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENOXAPARIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IN VITRO STUDY; PATIENT CARE; PERIPHERAL VASCULAR DISEASE; REVIEW; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; VASCULAR DISEASES;

EID: 1842419662     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002 ;13:37-40.
3. Howard PA. Aspirin resistance. Ann Pharmacother 2002 ;36:1620-4.
4. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002; 13-49-56.
5. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 9;105:1650-5.
6. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002;66:557-8.
7. Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989;84:1134-44.
8. Lassila R, Badimon JJ, Vallabhajosula S, et al. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: Effects of different stenosis on thrombus growth. Arteriosclerosis 1990;10:306-15.
9. Jorgensen L, Rowsell HC, Hovig T, et al. Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. Am J Pathol 1967;51:681-719.
10. Falk E. Morphologic features of unstable atherosclerotic plaques underlying acute coronary syndromes. Am J Cardiol 1989;663:114E-20.
11. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994;118:801-4.
12. Schror K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-56.
13. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002 ;41:458-61.
14. Bradbury J. Aspirin resistance may increase death risk in some patients with heart disease. Lancet 2002; 359:1128.
15. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994 ;25:2331-6.
16. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
17. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
18. Lancaster GI, Lancaster CJ, Radley D, Cohen M. Prior aspirin use in unstable angina predisposes to the higher risk: The aspirin paradox. Int J Cardiol 2001;80:201-7.
19. Garcia-Dorado D, Theroux P, Tornos P, et al. Previous aspirin use may attenuate the severity of the manifestations of acute ischemic syndromes. Circulation 1995;92:1743-8.
20. Cohen M, Adams PC, McBride R, Blanke H, Fuster V. Prospective comparison of patient characteristics and outcome of non-prior aspirin users versus aspirin users with unstable angina or non-Q-wave myocardial infarction treated with combination antithrombotic therapy. J Thromb Thrombolysis 1997;4:275-80.
21. Santopinto J, Gurfinkel EP, Torres V, et al. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001; 141:566-72.
22. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow up of aspirin responders and aspirin non-responders. A pilot study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
23. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
24. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D. Variable platelet response to low dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
25. Lassila R, Lepantalo M, Lindfors O. The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg 1991;15:378-82.
26. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591-5.
27. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schor K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance (letter). Lancet 1999;353: 900.
28. Cipololone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by ibuprofen and aspirin in patients with unstable angina. Circulation 1997;96:1109-16.
29. Kastrati A, Koch W, Gawaz M, Mehilli J, Bottiger C, Schomig K. P1A polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 2000;36:84-9.
30. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999;353:982-3.
31. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002 ;66:557-8.
32. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002; 13:49-56.
33. Gum PA, Kottke-Marchant K, Welsch PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
34. Lettino M, Cantu F, Mariani M. Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system. Dig Liver Dis 2001;33 (Suppl) 2: S12-20.